Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous CD133+ cells (Texas Heart Institute)
- Development stage
- Unknown
- Lead developer
- Texas Heart Institute
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intratumoral, Intravenous, Intracranial, Intra-arterial, Intraperitoneal, Subcutaneous
01
Overview
Autologous CD133+ cells are a population of progenitor cells, including endothelial progenitor cells (EPCs) and hematopoietic stem cells, isolated from a patient's own bone marrow or peripheral blood. These cells are characterized by the expression of the CD133 (Prominin-1) surface marker, which identifies a primitive cell subset with high regenerative and angiogenic potential. The therapeutic approach involves the isolation and selection of these cells—often using magnetic cell separation systems—followed by delivery to ischemic tissues, typically via transendocardial or intracoronary injection. Once delivered, these cells are intended to promote neovascularization and therapeutic angiogenesis, thereby improving blood flow and functional recovery in patients with cardiovascular conditions such as refractory angina, myocardial infarction, and peripheral artery disease.
- Other names
- selected CD133+ cellsCD133+ progenitor cellsautologous CD133+ endothelial progenitor cellsautologous CD133+ hematopoietic stem cells
Beyond the preview
Go deeper on autologous CD133+ cells (Texas Heart Institute).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous CD133+ cells (Texas Heart Institute).